Physician profile
John S Burrell
NPI 1528062197
$1,393.42
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $48.79 · 2021: $129 · 2022: $235 · 2023: $261 · 2024: $423 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $152.85 | 2019-2023 | Vivitrol |
| Janssen Pharmaceuticals, INC | $130.63 | 2019-2023 | Xarelto, Spravato |
| Novo Nordisk INC | $129.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $122.89 | 2022-2025 | Korlym |
| Gilead Sciences, INC. | $111.69 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.90 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.74 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $78.46 | 2019-2024 | Trelegy Ellipta |
| Philips North America LLC | $70.34 | 2020-2024 | (Ck7) Extended Holter |
| Axsome Therapeutics, INC. | $65.90 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $61.96 | 2021-2022 | |
| Cequr Corporation | $37.33 | 2024 | Cequr Simplicity |
| Intra-Sana Laboratories | $30.97 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Organon LLC | $29.33 | 2023 | |
| Teleflex LLC | $28.93 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.03 | 2025 | Id Now Instrument |
| Lilly USA, LLC | $19.02 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $18.69 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.56 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.96 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.94 | 2024 | |
| Allergan, INC. | $15.53 | 2019 | |
| Kyowa Kirin, INC. | $13.90 | 2023 | Crysvita |
| Merck Sharp & Dohme LLC | $13.57 | 2024 | Capvaxive, Vaxelis, Gardasil |
| Astrazeneca Pharmaceuticals LP | $12.69 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.